Pain Therapeutics Invites you to Join a Conference Call on Third Quarter 2018 Financial Results
23 Octobre 2018 - 1:30PM
Pain Therapeutics, Inc. (Nasdaq:PTIE), a biopharmaceutical company,
announced today it will release third quarter 2018 financial
results, and hold a conference call with a Q&A session, on
Monday, October 29, 2018 at 4:30 p.m. Eastern Time.
The Company’s conference call can be accessed by
dialing toll-free (877) 407-4018 (or 201 689-8471 for international
callers). A replay will be available toll-free at (844)
512-2921, (or 412 317-6671 for international callers), using the
conference ID code 13684539.
To listen to the Company’s webcast, please go to
http://www.paintrials.com/ and click on “News”, then “Event &
Presentations” to register. You may access
http://www.paintrials.com/ at any time through Monday, November
5th, 2018, for a replay of the webcast for this conference
call.
About the Company’s Neuroprotection
ProgramOur lead drug candidate, PTI-125, is a small
molecule with a unique mechanism of action for treating Alzheimer’s
disease (“AD”). We expect to initiate a Phase IIa study with
PTI-125 in AD in Q4 2018.
The underlying science for PTI-125 is published in
prestigious peer-reviewed journals, including Journal of
Neuroscience, Neurobiology of Aging, and Neuroimmunology and
Neuroinflammation, and benefits from several peer-reviewed research
grant awards from the NIH.
We are also developing a blood-based test,
called PTI-125Dx, to detect whether a person has Alzheimer’s
disease, possibly years before any symptoms appear. An early
diagnosis of AD could optimize treatment options and empower
physicians and patients to slow or halt the disease.
About Alzheimer's
DiseaseAlzheimer’s Disease (AD) is a progressive brain
disorder that destroys memory and thinking skills. Eventually, a
person with AD may be unable to carry out even the simplest
tasks. There is a profound and timely need to develop new
drugs for Alzheimer’s. Currently, there are no drug therapies
to halt Alzheimer’s, much less reverse its course.
About Pain Therapeutics, Inc.We
develop proprietary drugs and diagnostics that offer significant
improvements to patients and physicians. Our expertise consists of
developing new products and guiding these through various
regulatory and development pathways in preparation for their
eventual commercialization. The FDA has not yet established
the safety or efficacy of our product candidates.
Note Regarding Forward-Looking
Statements: This press release contains forward-looking
statements for purposes of the Private Securities Litigation Reform
Act of 1995 (the "Act"). Pain Therapeutics disclaims any
intent or obligation to update these forward-looking statements and
claims the protection of the Safe Harbor for forward-looking
statements contained in the Act. Examples of such statements
include, but are not limited to, statements regarding the timing of
clinical studies; and the potential benefits of the Company’s
program in Alzheimer’s disease. Such statements are based on
management's current expectations, but actual results may differ
materially due to various factors. Such statements involve
risks and uncertainties, including, but not limited to, those risks
and uncertainties relating to our financial and operational ability
to carry out development activities around Alzheimer’s
disease. For further information regarding these and other
risks related to our business, investors should consult our filings
with the U.S. Securities and Exchange Commission.
For More Information
Contact:
Eric SchoenChief Financial OfficerPain Therapeutics,
Inc.IR@paintrials.com (512) 501-2450
Pain Therapeutics (NASDAQ:PTIE)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Pain Therapeutics (NASDAQ:PTIE)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024